Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP 90 Return-on-Tangible-Asset is 16.83% as of Mar. 2026, which is 49% above its 10-year median of 11.30. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,009 Drug Manufacturers companies, AFT Pharmaceuticals ranks better than 83.25% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AFT Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was A$19.1 Mil. AFT Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was A$113.2 Mil. Therefore, AFT Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 16.83%.
The historical rank and industry rank for AFT Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
ASX:AFP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -30.94 Med: 11.3 Max: 25.43
Current: 11.77
During the past 11 years, AFT Pharmaceuticals's highest Return-on-Tangible-Asset was 25.43%. The lowest was -30.94%. And the median was 11.30%.
ASX:AFP's Return-on-Tangible-Asset is ranked better than 83.25% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs ASX:AFP: 11.77
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
AFT Pharmaceuticals Return-on-Tangible-Asset Related Terms
AFT Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.83% mean?
AFT Pharmaceuticals (ASX:AFP) has a Return-on-Tangible-Asset of 16.83% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AFT Pharmaceuticals and its competitors. This is 49% above median its historical median of 11.30. According to the industry distribution chart, AFT Pharmaceuticals ranks #169 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 16.7%.
Is AFT Pharmaceuticals' Return-on-Tangible-Asset too high?
AFT Pharmaceuticals' current Return-on-Tangible-Asset of 16.83% is 49% above median its 10-year median of 11.30. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. AFT Pharmaceuticals' value of 16.83% is 432.6% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #169 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #169 out of 1009 companies for Return-on-Tangible-Asset. This places AFT Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. AFT Pharmaceuticals' value of 16.83% is 432.6% above this benchmark. While the company's 10-year median is 11.30 vs. the industry median of 3.16, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Return-on-Tangible-Asset of 16.83% is 432.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Return-on-Tangible-Asset is 16.83%, which is 49% above median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Return-on-Tangible-Asset is 16.83%, which is 49% above median its 10-year median of 11.30 and 432.6% above the Drug Manufacturers industry median of 3.16. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Return-on-Tangible-Asset is 16.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
Return-on-Tangible-Asset: 16.83% (49% above median its 10-year median of 11.30)
GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
Industry Position: 432.6% above the Drug Manufacturers median (#169 of 1009)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score
Get the complete analysis for ASX:AFP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
